Gastrin and CCK activate phospholipase C and stimulate pepsinogen release by interacting with two distinct receptors
- PMID: 8476056
- DOI: 10.1152/ajpgi.1993.264.4.G718
Gastrin and CCK activate phospholipase C and stimulate pepsinogen release by interacting with two distinct receptors
Abstract
Both gastrin and cholecystokinin (CCK) can stimulate pepsinogen release from chief cells, but controversy exists about the receptors or intracellular mediators involved. In the present study, we prepared isolated chief cells from guinea pig stomach (> 90% pure) to investigate the ability of gastrin and CCK to alter cell function. The COOH-terminal octapeptide of CCK (CCK-8) caused an eightfold increase in pepsinogen release (EC50, 54 nM). Both CCK-8 and gastrin increased inositol phosphates, with CCK-8 (1 microM) and gastrin (3 microM) causing a 40- and 14-fold increase in [3H]IP1, 10- and 6-fold for [3H]IP2, and 8- and 4-fold for [3H]IP3. CCK-8 caused a half-maximal increase in [3H]IP3 at 2 nM, and the dose-response curve was monophasic, whereas with gastrin the curve was biphasic, with an EC50 of the initial component (20% maximal) at 38 nM and the second component at 10 microM. L-364,718 (0.1 microM) inhibited the secondary increase seen with gastrin concentrations > 10 nM. The CCK-A-selective agonist A-71378 was 85-90% as efficacious as CCK-8 and was equally potent. With 0.1 microM L-364,718, A-71378 caused no increase in [3H]inositol phosphates until > 10 nM, whereas CCK-8 caused 15% of maximal increase at concentrations > 0.3 nM. Similar results were obtained with cytosolic calcium measured using fura-2 or on CCK-8- or gastrin-stimulated pepsinogen release. These results demonstrate that gastrin and CCK-8 can alter chief cell function by interacting with either a CCK-A or CCK-B/gastrin receptor. Both receptors are coupled to phospholipase C and cause changes in inositol phosphates, cytosolic calcium, and pepsinogen release; however, the intracellular amplification differs between the two receptor subtypes. Activation by CCK-related peptides of the CCK-A receptor subtype accounts for 85-90% of the maximal changes in cellular function, and activation of the CCK-B/gastrin receptor accounts for 10-20% of maximal changes.
Similar articles
-
Both CCK-A and CCK-B/gastrin receptors mediate pepsinogen release in guinea pig gastric glands.Am J Physiol. 1992 Jun;262(6 Pt 1):G1113-20. doi: 10.1152/ajpgi.1992.262.6.G1113. Am J Physiol. 1992. PMID: 1616041
-
Partial agonism by gastrin for a cholecystokinin receptor mediating pepsinogen secretion.Am J Physiol. 1993 Nov;265(5 Pt 1):G865-72. doi: 10.1152/ajpgi.1993.265.5.G865. Am J Physiol. 1993. PMID: 8238515
-
CCK1 and CCK2 receptors regulate gastric pepsinogen secretion.Eur J Pharmacol. 1999 May 28;373(1):71-84. doi: 10.1016/s0014-2999(99)00212-5. Eur J Pharmacol. 1999. PMID: 10408253
-
Biology of gut cholecystokinin and gastrin receptors.Clin Exp Pharmacol Physiol. 1997 Mar-Apr;24(3-4):209-16. doi: 10.1111/j.1440-1681.1997.tb01809.x. Clin Exp Pharmacol Physiol. 1997. PMID: 9131287 Review.
-
Cellular localization of cholecystokinin receptors as the molecular basis of the periperal regulation of acid secretion.Pharmacol Toxicol. 2002 Dec;91(6):351-8. doi: 10.1034/j.1600-0773.2002.910612.x. Pharmacol Toxicol. 2002. PMID: 12688378 Review.
Cited by
-
Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects.Front Pharmacol. 2021 Nov 11;12:754849. doi: 10.3389/fphar.2021.754849. eCollection 2021. Front Pharmacol. 2021. PMID: 34867368 Free PMC article.
-
Pepsinogen secretion in cholecystokinin-1 receptor-deficient rats.Dig Dis Sci. 2004 Sep;49(9):1531-7. doi: 10.1023/b:ddas.0000042260.84749.ab. Dig Dis Sci. 2004. PMID: 15481333
-
Gastrin, Cholecystokinin, Signaling, and Biological Activities in Cellular Processes.Front Endocrinol (Lausanne). 2020 Mar 6;11:112. doi: 10.3389/fendo.2020.00112. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32210918 Free PMC article. Review.
-
A Comparison of Alkaline Water and Mediterranean Diet vs Proton Pump Inhibition for Treatment of Laryngopharyngeal Reflux.JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):1023-1029. doi: 10.1001/jamaoto.2017.1454. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 28880991 Free PMC article.
-
Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.BMC Gastroenterol. 2023 May 1;23(1):139. doi: 10.1186/s12876-023-02772-w. BMC Gastroenterol. 2023. PMID: 37127558 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources